Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by nodaytraderon Jan 17, 2022 4:06pm
128 Views
Post# 34325919

RE:RE:Price Drop

RE:RE:Price Drop

 OK! Let me try and explain with two caveats.
1. I am not knowledgeable about stock trading although I do watch it
https://www.thecse.com/en/listings/life-sciences/algernon-pharmaceuticals
2. 
I am not suggesting that there is anything illegal going on but there may be valid questions to be raised.

/> I think we both agree that that there some kind of price depression activity going on in that, whenever there is an announcement of good news for Algernon, the price goes down -just look at today's s activity as an example.<

 this not only affects value investors, ultimately it affects the sick, in that the low capital value produced by price depression hinders the company's ability to carry out research that could end or ameliorate that suffering.

Clearly, that is a public policy issue because that is what decides what is legal and what is not. So, my question is &quot;Should legislators be investigating this trading activity&quot;?

my second question is for regulators. Some of the traders involved provide investment advice to clients and, I lthink, would likely be licensed as such. But licensed financial advisers, I believe, have a fiduciary responsibility to clients, whickh means that client interests come first.

I can not see how price depression helps clients. So maybe a financial regulator should be looking at thiis.

to summarize. I am not saying that I think there is illegality but I think there are questions to be answered in order that investors and the general public can be assured that all is OK.

<< Previous
Bullboard Posts
Next >>